The development, over the past two decades, of small-molecule tyrosine kinase inhibitors (TKIs) targeting the fusion protein BCR-ABL1 expressed by the Philadelphia chromosome (Ph) has considerably advanced the treatment of chronic myeloid leukemia (CML) and Ph+ acute lymphoblastic leukemia (ALL). Here, ABL1 is linked to acute lymphoblastic leukemia.